2 withdrawn, 1 completed. 3 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 3 | Withdrawn 2, Completed 1 |
Follow Hypophosphatasia: new trials by email Literature Review of Hypophosphatasia trials Research Report on Hypophosphatasia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia methotrexate, rituximab, bortezomib - Hypophosphatasia | Phase 4 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2026-07-29 | 2025-12-18 | |
| Relieving Burden of Hypophosphatasia in Adults With Functional Impairment Due to Chronic Disease asfotase alfa - Hypophosphatasia | Phase 4 | Withdrawn | Alexion Pharmaceuticals, Inc. | 2020-04-01 | 2020-06-04 | |
| Post-approval Clinical Study of Asfotase Alfa Treatment for Patients With Hypophosphatasia (HPP) in Japan Asfotase Alfa - Hypophosphatasia | Phase 4 | Completed | Alexion Pharmaceuticals, Inc. | 13 | 2015-06-01 | 2017-05-08 |
Bone Diseases (1) · Osteomalacia (1) · Rickets (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Genetic Diseases, Inborn (3) · Metabolic Diseases (3) · Metabolism, Inborn Errors (3) · Metal Metabolism, Inborn Errors (3) · Nutritional and Metabolic Diseases (3) · Avitaminosis (1) · Bone Diseases, Metabolic (1) · Calcium Metabolism Disorders (1) · Deficiency Diseases (1) · Malnutrition (1) · Musculoskeletal Diseases (1) · Nutrition Disorders (1) · Vitamin D Deficiency (1)
asfotase alfa (2) · Bortezomib (1) · Folic Acid (1) · Immunoglobulins, Intravenous (1) · Methotrexate (1) · Rituximab (1)
Alexion Pharmaceuticals, Inc. (3)
Kenji Fujita, MD (1)